PwPepwise

Setmelanotide

Skin & Tanning

a.k.a. Imcivree

MC4R agonist

Setmelanotide is a targeted injectable peptide that works by activating a specific brain receptor — the melanocortin-4 receptor (MC4R).

§Dosing at a glance

2 protocols · from the research
What it's forDoseHow oftenHowFor how long
Adults and pediatric patients ≥12 years (BBS, POMC/LEPR deficiency)3.0 mgOnce dailySubcutaneousInjected just under the skin, into the fat layer.—
Pediatric patients aged 2–5 years0.5 mgOnce dailySubcutaneousInjected just under the skin, into the fat layer.—

Approximate values pulled from the research — double-check before dosing.

§01Summary

Setmelanotide is a targeted injectable peptide that works by activating a specific brain receptor — the melanocortin-4 receptor (MC4R) — to restore the body's natural ability to regulate hunger and body weight. In people with certain rare genetic conditions that disrupt this signaling pathway, the MC4R circuit becomes impaired, leading to severe, unrelenting hunger and early-onset obesity that is resistant to conventional diet and lifestyle interventions. By directly engaging MC4R, setmelanotide essentially bypasses the broken upstream signals and reactivates the body's energy balance system.

Setmelanotide reduces body weight in patients with Bardet-Biedl syndrome (BBS), a rare genetic ciliopathy: in a pivotal phase 3 trial, 32.3% of BBS patients aged 12 and older achieved at least 10% body weight loss after 52 weeks of treatment1. In very young children aged 2–5 with MC4R pathway-associated genetic obesity, treatment appears to reduce BMI substantially, with 83% of participants in one open-label trial achieving the primary BMI endpoint17. Meaningful weight loss in BBS patients has also been associated with reductions in metabolic syndrome severity, including lower estimated risks of cardiovascular disease and type 2 diabetes18. Setmelanotide is administered as a once-daily subcutaneous injection and is generally well tolerated, with skin darkening (hyperpigmentation) and injection site reactions being the most commonly reported effects1,17.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Setmelanotide is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) engineered to function as a selective, potent agonist of the melanocortin-4 receptor (MC4R), a G protein-coupled receptor predominantly expressed in hypothalamic neurons of the paraventricular nucleus. MC4R sits at the convergence of the leptin-melanocortin energy homeostasis axis: under physiological conditions, leptin secreted by adipose tissue signals through the leptin receptor (LEPR) on hypothalamic POMC neurons, stimulating cleavage of proopiomelanocortin (POMC) — via the proprotein convertase PCSK1 — into α-MSH, which binds and activates MC4R to suppress appetite and increase energy expenditure. Loss-of-function mutations in POMC, PCSK1, or LEPR upstream of MC4R, or disruption of ciliary MC4R trafficking as occurs in ciliopathies such as Bardet-Biedl syndrome, impair this cascade, producing severe hyperphagia and early-onset obesity1,11.

Setmelanotide bypasses these upstream defects by directly engaging MC4R, activating Gαs-mediated intracellular signaling — primarily cyclic AMP (cAMP) production — that recapitulates the anorectic and metabolic effects of endogenous α-MSH. This mechanism distinguishes setmelanotide from broadly acting obesity pharmacotherapies, as its efficacy is contingent on functional downstream MC4R signaling being preserved or partially intact. The differential response magnitude observed between POMC/LEPR deficiency patients and BBS patients — where POMC/LEPR patients show greater mean BMI reductions (-26% vs. -10%)17 — is consistent with BBS ciliopathy producing a partial rather than complete disruption of MC4R pathway function, supporting disease-specific gradations in pathway impairment1,17.

The cyclic peptide structure of setmelanotide confers metabolic stability relative to linear α-MSH analogs, enabling subcutaneous administration with sustained receptor engagement. Therapeutic dosing in adults reaches up to 3.0 mg/day via subcutaneous injection1, with a weight-based pediatric titration schedule starting at 0.5 mg/day and escalating in 0.5 mg increments every 2 weeks17. Pharmacokinetic characterization across renal function strata is actively being conducted, given the potential for altered drug exposure in patients with obesity-associated renal dysfunction20.

Beyond weight regulation, MC4R agonism produces downstream effects on metabolic syndrome parameters: setmelanotide-driven weight loss in BBS patients is associated with significant reductions in MetS-Z-BMI scores (a composite metabolic syndrome severity metric), with responders showing mean reductions of 0.64 points versus 0.08 in non-responders (p=0.0043), translating to substantially reduced estimated cardiovascular disease and type 2 diabetes risk18. The drug's pigmentary effects — skin hyperpigmentation observed in 61% of treated patients1 — reflect off-target agonism at MC1R on melanocytes, a predictable pharmacological consequence of melanocortin pathway engagement at the receptor level.

§04Evidence & efficacy

Evidence base
237Studies
112Human
14Animal

Setmelanotide reduces body weight in patients with Bardet-Biedl syndrome: in a multicentre, randomised, double-blind, placebo-controlled phase 3 trial, 32.3% of BBS patients aged ≥12 years achieved ≥10% body weight reduction after 52 weeks (p=0.0006), representing the primary endpoint1. A subsequent analysis comparing phase 3 trial participants against a propensity-matched natural history registry cohort (CRIBBS) found that 58.6% of setmelanotide-treated BBS patients met the predefined weight endpoint versus 6.9% of controls (p<0.001), with consistent benefit across both pediatric (71.4% vs. 10.7%) and adult (46.7% vs. 3.3%) subgroups11.

In children aged 2–5 years with MC4R pathway-associated genetic obesity, setmelanotide appears to substantially reduce BMI, with 83% of participants achieving ≥0.2-point reduction in BMI Z-score at week 52 and a mean BMI percent change of -18% overall in one open-label trial17. Patients with POMC/LEPR deficiency showed a larger mean BMI reduction (-26%) compared to BBS patients (-10%) in that study17.

Weight loss in BBS patients achieving clinically meaningful weight reduction thresholds is associated with reductions in metabolic syndrome severity scores and lower estimated cardiovascular and type 2 diabetes risk compared to non-responders18. Efficacy in Alström syndrome patients was inconclusive in the pivotal trial due to the very small sample size enrolled1.

Setmelanotide's efficacy is being actively investigated in additional genetically defined obesity subtypes including heterozygous POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 variants under an ongoing phase 3 umbrella protocol3. Emerging genetic evidence suggests that the patient selection framework for some of these sub-studies — particularly those targeting heterozygous LEPR variants — may warrant refinement, as large-scale cohort data indicate that monoallelic pathogenic LEPR variants do not independently elevate obesity risk2. Similarly, for PCSK1 variants, functional assay evidence indicates that only heterozygous null or complete loss-of-function variants, not partial loss-of-function variants, are likely to confer obesity susceptibility, underscoring the importance of rigorous functional variant classification before treatment decisions14.

Efficacy in acquired hypothalamic obesity is currently being investigated in two registered phase 3 placebo-controlled trials4,9, with results pending.

§05Safety

Setmelanotide has a well-characterized tolerability profile across multiple clinical trials. The most consistently reported adverse effects are skin hyperpigmentation, observed in 61% of BBS patients in the pivotal phase 3 trial, and injection site erythema, reported in 48% of participants in the same study1. These effects are mechanistically expected consequences of MC4R agonism and stimulation of melanocortin receptors in melanocytes.

In very young children aged 2–5 years, all adverse events reported in the VENTURE trial were mild or moderate in severity. Common events in that population included skin hyperpigmentation, vomiting, nasopharyngitis, upper respiratory tract infection, and injection site reactions, with no serious adverse events, no discontinuations due to adverse events, and no deaths over 52 weeks17.

In the pivotal BBS/Alström phase 3 trial, four serious adverse events were reported in two patients — blindness, an anaphylactic reaction, and suicidal ideation — none of which were considered related to setmelanotide by the investigators1. Post-hoc metabolic analyses did not identify new safety signals18.

Long-term safety data across the full eligible population are actively being collected through an open-label extension study enrolling patients as young as 2 years across multiple rare MC4R pathway disease etiologies19. Cardiac safety, specifically QTc interval prolongation, has been evaluated in a dedicated thorough QT study at therapeutic and supratherapeutic concentrations per ICH E14 guidance, though full results from that study have not been published in peer-reviewed literature5.

§06History

Setmelanotide (originally designated RM-493) was developed by Rhythm Pharmaceuticals as a precision pharmacotherapy targeting the melanocortin-4 receptor in genetically defined obesity. The compound emerged from decades of foundational research establishing the leptin-POMC-MC4R axis as a central regulator of human energy homeostasis, with landmark genetic discoveries in the late 1990s and 2000s identifying biallelic loss-of-function mutations in POMC, PCSK1, and LEPR as causes of severe early-onset obesity. These discoveries created the mechanistic rationale for MC4R agonism as a therapeutic strategy in affected patients.

Early-phase clinical evaluation began with phase 1 multiple ascending dose studies in obese volunteers and patients with MC4R pathway variants, exploring subcutaneous once- and twice-daily dosing formulations10,15. Phase 1b/2a studies characterized the dose-response relationship for weight loss and established the pharmacokinetic and pharmacodynamic profile15. Pivotal phase 3 trials subsequently enrolled patients with biallelic POMC/PCSK1 deficiency12, biallelic LEPR deficiency6, and Bardet-Biedl/Alström syndromes7, with the BBS trial results published in 2022 demonstrating statistically significant weight loss meeting the primary endpoint1.

Setmelanotide received FDA approval for POMC, PCSK1, and LEPR deficiency obesity, and subsequently for Bardet-Biedl syndrome — representing the first pharmacotherapy specifically indicated for BBS-associated obesity1. The clinical program has since expanded to include pediatric patients as young as 2 years16,17, once-weekly formulation development8, and investigation of additional MC4R pathway gene variants and acquired hypothalamic obesity indications3,4,9,13, with an open-label extension study ongoing19.

§07References